FdaApplication
NDA 204677
Identifiers
- fda_app_no: NDA204677
Properties
| Property | Value |
|---|---|
| applicant_name | LANTHEUS BIOSCIENCES LTD |
| application_type | NDA |
| approval_date | 2014-03-19 |
Revenue by product
NEURACEQ
| Period | Revenue |
|---|---|
| Q4 2025 | $31.0M |
| Q3 2025 | $20.4M |
| Q4 2024 | $0.0M |
| Q3 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NEURACEQ | FLORBETABEN F-18 | 1.4-135mCi/ML | SOLUTION;INTRAVENOUS |
1 product